Xenetic Biosciences, Inc. — 2016 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2016. This is an annual report; the supplied filing text does not provide a separate fourth-quarter income statement. Financial figures below compare full-year 2016 with full-year 2015.
Business context
Xenetic is a clinical-stage biopharmaceutical company developing orphan oncology candidates and biologic drug-delivery technologies. Its lead internal candidate, XBIO-101, is being developed for progesterone-receptor-negative endometrial cancer; its PolyXen platform is designed to extend the circulation time of biologic drugs. No candidate had received marketing approval by year-end. The company reported more than 200 issued patents and approximately 100 pending applications.
Financial performance and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $3.0 million | None |
| Research and development expense | $43.74 million | $3.43 million |
| General and administrative expense | $6.69 million | $6.39 million |
| Operating loss | $47.43 million | $9.82 million |
| Net loss | $54.21 million | $12.51 million |
| Net loss per share applicable to common stockholders | $7.84 | $2.96 |
| Cash used in operating activities | $8.79 million | $5.30 million |
- All 2016 revenue was a $3 million Shire milestone for SHP656’s clinical advancement. It was earned in December 2016 and collected in January 2017. No cost of revenue was reported; product margins are not meaningful because there were no product sales.
- R&D expense included a $39.5 million noncash charge for acquired XBIO-101 in-process research and development, recorded when the asset acquisition closed. Excluding that item, R&D expense increased about $804,000, or 23%, year over year.
- Other significant 2016 charges included a $6.39 million loss on debt conversion, a $1.69 million loss on issuance of hybrid debt instruments, and $730,000 of interest expense. A $2.13 million gain from changes in derivative fair value partly offset these items. The preferred-stock beneficial-conversion-feature accretion was $4.04 million and increased the loss applicable to common stockholders.
- Year-end cash was $4.05 million, plus $66,510 of restricted cash. Working capital was approximately $6.5 million, versus a $3.2 million deficit in 2015. Total assets were $20.97 million and total liabilities $4.80 million. Accounts payable and accrued expenses totaled about $1.85 million.
- There were no hybrid debt instruments outstanding at December 31, 2016; notes were converted, settled, or applied to the public offering. Year-end liabilities included a $2.92 million deferred tax liability. Financing activities provided $12.72 million, including $4.5 million of debt proceeds and $8.97 million of net public-offering proceeds.
Material changes and developments
- R&D and net losses rose sharply, principally because of the $39.5 million XBIO-101 acquired IPR&D charge. Net operating cash use also increased by about $3.49 million.
- In April 2016, Xenetic acquired specified XBIO-101 intellectual-property rights and issued 3,045,455 shares to Pharmsynthez. Pharmsynthez also converted $6.5 million of principal plus accrued interest into common stock.
- In November 2016, the company completed a $10 million gross public offering of preferred-stock-and-warrant units and began trading on Nasdaq. Net cash proceeds were reported as $8.97 million; offering units also included conversion of $500,000 of notes.
- Common shares outstanding increased from 4.59 million at year-end 2015 to 8.41 million at year-end 2016. Series A and Series B preferred shares were also outstanding and convertible into common shares. Pharmsynthez owned approximately 52.6% of issued common stock at year-end.
Outlook, commentary, and key risks
- Management estimated that existing resources and anticipated first-half 2017 revenue would fund planned operations and commitments only through the first half of 2017. The company had no committed source of additional capital and stated it would need to raise working capital during 2017.
- Management and the auditor cited recurring losses and negative operating cash flows as raising substantial doubt about the company’s ability to continue as a going concern. The audited statements were prepared on a going-concern basis and include no adjustments for a possible inability to continue.
- Xenetic planned to advance XBIO-101 into a U.S. Phase 2 trial, with first-patient enrollment expected in Q2 2017. Shire expected SHP656 Phase 1/2 results in Q2 2017; a further milestone payment was possible but contingent on clinical progress. These are forward-looking plans, not assured outcomes.
- ErepoXen development was on hold while Xenetic sought an out-license; OncoHist development was also on hold pending sufficient capital. Internal development focus was limited by funding constraints.
- Key risks include dependence on future financing and partner milestones, clinical and regulatory failure or delay, reliance on third-party manufacturers and collaborators, competition, intellectual-property challenges, and potential dilution. Shire accounted for more than 90% of milestone revenue received to date. Major shareholders and related-party counterparties include Pharmsynthez, SynBio, and Serum Institute.
- No material legal proceedings were reported as of December 31, 2016. Goodwill and indefinite-lived intangible assets were not impaired in 2016, but their recoverability could be affected by the going-concern uncertainty.
Important facts for investors to verify
- Whether Xenetic obtained financing after the filing date, on what terms, and whether it extended the stated runway beyond the first half of 2017.
- Actual XBIO-101 Phase 2 enrollment, trial progress, safety findings, and regulatory developments relative to the company’s expected timing.
- Shire’s SHP656 trial results and whether any additional milestone was achieved and collected.
- The composition and terms of outstanding preferred shares, warrants, and other potential dilution, including the effect of future conversions or financings.
- The basis and sustainability of future collaboration or licensing revenue, given the concentration in Shire and the absence of product sales.